Clinical Trials Browser

Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Nausea, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms

NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Phase 2 Completed

54 enrolled 7 charts

Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

NCT00064272 2016-10-21

IRB 2003-551

Phase 2 Completed

180 enrolled

Nausea, Vomiting

NCT02787707 2016-06-03

Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting

Phase 2 Completed

69 enrolled

Breast

Breast Neoplasms, Nausea, Vomiting

NCT01736917 2016-05-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Phase 2 Completed

65 enrolled 14 charts

Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Vomiting

NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Phase 2 Unknown

80 enrolled

Thoracic

Lung Neoplasms, Nausea, Vomiting

NCT00003817 2015-10-15

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

Phase 2 Completed

700 enrolled

Nausea, Vomiting

NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Phase 2 Completed

100 enrolled 7 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02407600 2015-04-03

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Phase 2 Unknown

150 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Nausea, Vomiting

NCT00450853 2015-01-27

Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients

Phase 2 Completed

31 enrolled

Vomiting

NCT01788605 2014-12-08

Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation

Phase 2 Unknown

65 enrolled

Other hematologic neoplasm

Vomiting, Hematologic Neoplasms

NCT02290470 2014-11-14

Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

Phase 2 Unknown

81 enrolled

Nausea, Vomiting

NCT02234466 2014-09-09

Preoperative Oral Dexamethasone to Improve Recovery After Surgery

Phase 2 Unknown

80 enrolled

Breast

Breast Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT01012336 2012-10-10

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Phase 2 Completed

89 enrolled 7 charts

Gynecologic

Ovarian Neoplasms, Vomiting

NCT00004895 2012-06-06

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Phase 2 Completed

GastrointestinalGynecologicOtherSarcoma

Carcinoma, Ovarian Epithelial, Bile Duct Neoplasms, Colonic Neoplasms, Constipation, Intestinal Obstruction, Nausea, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT01046461 2012-02-17

RAD

Phase 2 Unknown

41 enrolled

Nausea, Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT00666783 2008-04-25

An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

Phase 2 Completed

208 enrolled

Vomiting

Clinical Trials

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

GIM15-NEPA

Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

HDIL2/Emend

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

IRB 2003-551

Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients

Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation

Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

Preoperative Oral Dexamethasone to Improve Recovery After Surgery

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

RAD

An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients